

## Supplementary Online Content

Rasmussen KM, Patil V, Li C, et al. Survival outcomes by race and ethnicity in veterans with nonmetastatic, castration-resistant prostate cancer. *JAMA Netw Open*. 2023;6(10):e2337272. doi:10.1001/jamanetworkopen.2023.37272

**eTable.** Treatments for nmCRPC by Race, Ethnicity, and Epoch

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable. Treatments for nmCRPC by race, ethnicity, and epoch**

Patients, n (%)	All N=12,992	Hispanic n=826	Non-Hispanic Black n=3,671	Non-Hispanic White n=7,323	Other*/ Unknown n=1,172
<b>Treatment</b>					
ADT only	7,855 (60)	534 (65)	2,269 (62)	4,365 (60)	687 (59)
Abiraterone ± ADT	232 (2)	7 (1)	35 (1)	165 (2)	25 (2)
Bicalutamide ± ADT	3,085 (24)	194 (23)	882 (24)	1,736 (24)	273 (23)
Enzalutamide ± ADT	159 (1)	5 (1)	30 (1)	107 (1)	17 (1)
Finasteride ± ADT	420 (3)	26 (3)	104 (3)	243 (3)	47 (4)
Ketoconazole ± ADT	19 (0.1)	**	**	13 (0.2)	**
Other ± ADT	177 (1.4)	8 (1)	47 (1.3)	103 (1.4)	19 (1.6)
No treatment	1,045 (8.0)	51 (6.1)	301 (8.2)	591 (8.1)	102 (8.7)
<b>Treatment Epoch</b>					
Before 2013	5,217 (40)	280 (34)	1,390 (38)	2,971 (41)	576 (49)
2013 and after	7,775 (60)	546 (66)	2,281 (62)	4,352 (59)	596 (51)
Abbreviations: ADT: androgen deprivation therapy; nmCRPC: non-metastatic castration-resistant prostate cancer					
* <i>Other</i> includes American Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, unknown by patient, and patient declined to answer.					
** Fewer than 5 patients identified					